Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION (NDA) OF DEUNOXAVIR MARBOXIL GRANULES WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that, on September 3, 2025, the new drug application (NDA) of Deunoxavir Marboxil Granules (Xianlinda®), an anti-influenza drug, jointly developed by the Group and Jiaxing AnDiCon Biotech Co., Ltd.* (嘉興安帝康生物科技有限公司) ("**AnDiCon**"), was accepted by the National Medical Products Administration (NMPA), for treating uncomplicated influenza A and influenza B in 2 to 11-year-old pediatric patients. Deunoxavir Marboxil Granules is China's first pediatric anti-influenza virus innovative drug which successfully completes the phase III clinical trial and regulatory approval.

ABOUT DEUNOXAVIR MARBOXIL

Deunoxavir Marboxil functions as a cap-dependent endonuclease inhibitor. Deunoxavir Marboxil's mechanism of action is to inhibit the cap-dependent endonuclease that is essential for influenza virus replication, thereby blocking the transcription of the virus's mRNA and precisely suppressing viral replication.

Clinical studies indicated that the Deunoxavir Marboxil Granules demonstrated potential clinical advantages including favorable safety profiles in pediatric patients, faster symptom relief and viral clearance, lower risk of resistance, no effect of food intake on oral drug and a dosage form better suited for pediatric patients.

ABOUT ANDICON

Led by a number of academicians, the scientific and technological innovation team of AnDiCon focuses on the fields of respiratory infection, analgesia and CNS, and established a new drug R&D system based on metabolic differentiation leveraging the DMPK platform. In addition to the new anti-influenza drug Deunoxavir Marboxil (ADC189) pipeline, the product pipeline of AnDiCon also includes a number of innovative drugs such as ADC308, an innovative gynecological drug for assisted reproduction; ADC-M9, a novel CNS drug featuring an innovative compound oral muscarinic formulation; and ADC558, a new non-opioid analgesic drug, etc.

ABOUT THE COMPANY

The Company is an innovation and R&D-driven pharmaceutical company and has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Company focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "for patients, for life". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. REN Jinsheng
Chairman and Chief Executive Officer

Hong Kong, September 3, 2025

* *For indicative purpose only*

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.